Top

Annals of Nuclear Medicine

Published in:

01-11-2019 | Positron Emission Tomography | Original Article

A pitfall of white matter reference regions used in [¹⁸F] florbetapir PET: a consideration of kinetics

Authors: Masashi Kameyama, Kenji Ishibash, Kei Wagatsuma, Jun Toyohara, Kenji Ishii

Published in: Annals of Nuclear Medicine | Issue 11/2019

Abstract

Objective

Many studies have demonstrated the superiority of white matter (WM) reference regions (RR) in amyloid PET studies in comparison to cerebellar RR. However, the principle behind its improved measurement stability is yet to be elucidated. Our study aimed to determine the origin of WM stability; stability over cerebral blood flow and input function fluctuation or the greater statistical noise in the cerebellum due to its smaller size and its location in the axial periphery of the PET scanner bore.

Methods

We conducted simulations of [\({}^{18}\)F] florbetapir using in-house program varying \(K_1\) and input function, and adding statistical noise.

Results

Our simulations revealed that WM RR were more susceptible to CBF variation and input function fluctuation than cerebellar RR. WM RR did not gave superior measurement stability unless cerebellar statistical noise exceeded 4.55 times that in WM, a figure often surpassed in traditional amyloid PET studies. The greater statistical noise in cerebellum is likely the etiology for improved measurement stability of WM RR.

Conclusion

A longitudinal [\({}^{18}\)F] florbetapir PET study should be conducted with a long bore PET. It can also be hypothesized that a second scan with the cerebellum in the axial center of a 3D PET, using a cerebellar RR to calculate changes in tracer concentration may improve the measurement stability of longitudinal [\({}^{18}\)F] florbetapir studies.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19. https://doi.org/10.1002/ana.20009.CrossRefPubMed

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimer’s Dement. 2017;13(10):1117–24. https://doi.org/10.1016/j.jalz.2017.02.009.CrossRef

Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand’Maison M, O’Neill P, et al. Impact of reference/target region selection on amyloid PET standard uptake value ratios in the phase 1b PRIME study of aducanumab. J Nucl Med. 2019;60(1):100–106. https://doi.org/10.2967/jnumed.118.209130.CrossRefPubMed

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9. https://doi.org/10.1038/sj.jcbfm.9600493.CrossRefPubMed

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834–40. https://doi.org/10.1097/00004647-199609000-00008.CrossRefPubMed

Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3):153–8. https://doi.org/10.1006/nimg.1996.0066.CrossRefPubMed

Lammertsma AA. Forward to the past: the case for quantitative PET imaging. J Nucl Med. 2017;58(7):1019–24. https://doi.org/10.2967/jnumed.116.188029.CrossRefPubMed

van Berckel B, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using \({}^{11}\)C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570–6. https://doi.org/10.2967/jnumed.112.113654.CrossRefPubMed

Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [\({}^{18}\)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450–9. https://doi.org/10.1016/j.neuroimage.2014.11.055.CrossRefPubMed

10.

Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-\(\beta\) PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56(4):560–6. https://doi.org/10.2967/jnumed.114.149732.CrossRefPubMed

11.

Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \(\beta\)-amyloid change with \({}^{18}\)F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56(4):567–74. https://doi.org/10.2967/jnumed.114.148981.CrossRefPubMed

12.

Blautzik J, Brendel M, Sauerbeck J, Kotz S, Scheiwein F, Bartenstein P, et al. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. Eur J Nucl Med Mol Imaging. 2017;44(8):1364–74. https://doi.org/10.1007/s00259-017-3666-8.CrossRefPubMed

13.

Ottoy J, Verhaeghe J, Niemantsverdriet E, Wyffels L, Somers C, De Roeck E, et al. Validation of the semiquantitative static SUVR method for \({}^{18}\)F-AV45 PET by pharmacokinetic modeling with an arterial input function. J Nucl Med. 2017;58(9):1483–9. https://doi.org/10.2967/jnumed.116.184481.CrossRefPubMed

14.

Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N. Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. J Alzheimer’s Dis. 2015;43(3):809–21. https://doi.org/10.3233/JAD-131979.CrossRef

15.

Schwarz CG, Senjem ML, Gunter JL, Tosakulwong N, Weigand SD, Kemp BJ, et al. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage. 2017;144:113–27. https://doi.org/10.1016/j.neuroimage.2016.08.056.CrossRefPubMed

16.

Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longitudinal amyloid-\(\beta\) change with \({}^{18}\)F-Florbetaben PET. J Nucl Med. 2017;58(8):1300–6. https://doi.org/10.2967/jnumed.116.187351.CrossRefPubMed

17.

Valentina G, Silvia M, Marco P. Dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging. 2016;43(7):1300–3. https://doi.org/10.1007/s00259-016-3393-6.CrossRefPubMed

18.

Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28(6):696–703. https://doi.org/10.1007/s002590100537.CrossRefPubMed

19.

Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, et al. Relative \({}^{11}\)C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session \({}^{15}\)O-water and \({}^{11}\)C-PiB PET. J Nucl Med. 2015;56(8):1199. https://doi.org/10.2967/jnumed.114.152405.CrossRefPubMed

20.

Cselényi Z, Farde L. Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. J Cereb Blood Flow Metab. 2015;35(9):1485–93. https://doi.org/10.1038/jcbfm.2015.66.CrossRefPubMedPubMedCentral

21.

Schwarz CG, Jones DT, Gunter JL, Lowe VJ, Vemuri P, Senjem ML, et al. Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements. Hum Brain Mapp. 2017;38(7):3323–36. https://doi.org/10.1002/hbm.23622.CrossRefPubMedPubMedCentral

22.

Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988;241(4864):462–4. https://doi.org/10.1126/science.3260686.CrossRefPubMed

23.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal \({}^{18}\)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimer’s Res Ther. 2016;8(1):2. https://doi.org/10.1186/s13195-016-0172-3.CrossRef

24.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer’s disease: results from the DIAN study group. PLoS ONE. 2016;11(3):e0152082. https://doi.org/10.1371/journal.pone.0152082.CrossRefPubMedPubMedCentral

25.

Oliveira F, Leuzy A, Castelhano J, Chiotis K, Hasselbalch SG, Rinne J, et al. Data driven diagnostic classification in Alzheimer’s disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A\(\beta\) species. NeuroImage: Clinical. 2018;20:603–10. https://doi.org/10.1016/j.nicl.2018.08.023.

26.

Ito H, Ikoma Y, Seki C, Kimura Y, Kawaguchi H, Takuwa H, et al. Visual evaluation of kinetic characteristics of PET probe for neuroreceptors using a two-phase graphic plot analysis. Ann Nucl Med. 2017;31(4):273–82. https://doi.org/10.1007/s12149-017-1155-6.CrossRefPubMed

27.

Ottoy J, Verhaeghe J, Niemantsverdriet E, Engelborghs S, Stroobants S, Staelens S. A simulation study on the impact of the blood flow-dependent component in [\({}^{18}\)F] AV45 SUVR in Alzheimer’s disease. PloS ONE. 2017;12(12):e0189155. https://doi.org/10.1371/journal.pone.0189155.CrossRefPubMedPubMedCentral

28.

Baron J, Bousser M, Comar D, Soussaline F, Castaigne P. Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo. Eur Neurol. 1981;20(3):273–84. https://doi.org/10.1159/000115247.CrossRefPubMed

29.

Lacalle-Aurioles M, Alemán-Gómez Y, Guzmán-De-Villoria JA, Cruz-Orduña I, Olazarán J, Mateos-Pérez JM, et al. Is the cerebellum the optimal reference region for intensity normalization of perfusion MR studies in early Alzheimer’s disease? PloS ONE. 2013;8(12):e81548. https://doi.org/10.1371/journal.pone.0081548.CrossRefPubMedPubMedCentral

30.

Lowe VJ, Lundt ES, Senjem ML, Schwarz CG, Min HK, Przybelski SA, et al. White matter reference region in PET studies of \({}^{11}\)C-Pittsburgh Compound B uptake: effects of age and amyloid-\(\beta\) deposition. J Nucl Med. 2018;59(10):1583–9. https://doi.org/10.2967/jnumed.117.204271.

Title: A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics
Authors: Masashi Kameyama
Kenji Ishibash
Kei Wagatsuma
Jun Toyohara
Kenji Ishii
Publication date: 01-11-2019
Publisher: Springer Singapore
Keyword: Positron Emission Tomography
Published in: Annals of Nuclear Medicine / Issue 11/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-019-01397-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A pitfall of white matter reference regions used in [¹⁸F] florbetapir PET: a consideration of kinetics

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2019

Computer-aided detection of bone metastasis in bone scintigraphy images using parallelepiped classification method

Searching for diagnostic properties of novel fluorine-18-labeled d-allose

18F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading

4′-[methyl-11C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with 18F-FDG

In vivo preclinical PET/CT imaging of carbon-11-labeled aminoglycerol probe for the diagnosis of liver fibrosis

Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials